EUCTR2021-000349-42-SEActive, not recruitingPhase 1
Evaluation of the Durability of Immune Responses to SARS-CoV-2 Using Novel Rapid Spike Interferon-Gamma Release and Activation-Induced Marker Assays and Anti-Spike IgG Following COVID-19 Vaccination
Sahlgrenska Academy, University of Gothenburg0 sites500 target enrollmentStarted: February 8, 2021Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 500
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. All participants must give written informed consent
- •2. Woman or man aged 18 years or older
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 400
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
Exclusion Criteria
- •1. Inability to give written informed consent
- •2. Inability to undergo blood sampling, e.g. due to lack of suitable blood vessels for sampling
Investigators
Similar Trials
Completed
Phase 3
Durability of Immunogenicity and Effectiveness of the heterologous COVID-19 vaccination in kidney transplant recipientsImmunogenicity of the vaccineEffectiveness of the vaccinehumoral immunity, cell-mediated immunity, SARS-CoV-2, immunization, immunocompromisedTCTR20220511002ational Council Researach of Thailand100
Completed
Not Applicable
Investigation of the immunogenicity and durability of second COVID-19 vaccine booster dose and their associations with the background factorsRegardless of the type of diseaseJPRN-UMIN000048396Department of Pulmonology and Gerontology, Graduate School of Medicine, Yamaguchi University100
Completed
Not Applicable
Background factors affecting the effectiveness of the COVID-19 vaccine and their association with the microbiomes in the oral cavity and intestinal tractRegardless of the type of diseaseJPRN-UMIN000043558Department of Pulmonology and Gerontology, Graduate School of Medicine, Yamaguchi University180
Completed
Not Applicable
Prospective study on evaluation of immune response after SARS-CoV-2 vaccinatioHealthy SubjectJPRN-UMIN000045492Shionogi & Co., Ltd.143
Not yet recruiting
Phase 4
A 9th year follow up study on persitance of Hepatitis A vaccineCTRI/2017/02/007837Wockhardt Ltd150